PDCD1 and lung cancer: Immune checkpoint inhibitors, including anti–programmed cell death 1 (anti–PD-1) antibody and anti–programmed cell death ligand 1 (anti–PD-L1) antibody, have shown remarkable clinical benefits in certain cancer types, such as melanoma and lung cancer (2, 3), but have limited efficacy in OV (4).